New Blood-Saving tactics aim to cut transfusions in kidney cancer surgery
NCT ID NCT04922307
First seen Nov 12, 2025 · Last updated Jun 22, 2026 · Updated 33 times
Summary
This study tests special blood-sparing techniques during surgery for advanced kidney cancer. The goal is to reduce the number of donor blood transfusions patients need. About 240 adults with large kidney tumors will be randomly assigned to receive either the blood-sparing protocol or standard care. Researchers will also track complications and long-term outcomes like cancer recurrence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
H. Lee Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
-
Winship Cancer Institute at Emory University
Atlanta, Georgia, 30322, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Blood-sparing techniques (acute normovolemic hemodilution, cell saver, veno-venous bypass)
What this could lead to
If successful, this approach could reduce complications and improve recovery for patients undergoing surgery for advanced kidney cancer.
What could go wrong
This is a relatively small, single-center study, and the techniques may not significantly reduce transfusions or improve outcomes in all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.